Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bridge program keeps seizure drug available for eligible patients

NCT ID NCT02307578

Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended) This study
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This program provides continued access to the seizure medication perampanel (Fycompa) for people who completed certain earlier studies and are still benefiting from the drug. It runs until the drug is commercially available in their country or no participants remain. Only those already in the program or specific prior studies are eligible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Perampanel (also known as Fycompa)
What this could lead to
If successful, this program ensures continued access to perampanel for people with certain seizure disorders until the drug is commercially available in their country.
What could go wrong
This is an access program, not a new trial, so it does not test new benefits or risks. Participants must have already shown a positive response to perampanel in prior studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Participants who have completed their participation in Study E2007-G000-332, Study E2007-G000-311, E2007-G000-238, E2007-G000-338, or who are being rolled over from EAP E2007-G000-401 and, who in the opinion of the treating physician, continue to demonstrate a positive benefit-to-risk ratio from treatment with perampanel. 2. Participants who provide informed consent where applicable per local requirements. 3. Female participants of childbearing potential must agree for the duration of the program and for a period of at least 1 month following last dose of perampanel to be abstinent or to commit to the consistent and correct use of a medically acceptable method of birth control (example, a double-barrier method \[condom plus spermicide, condom plus diaphragm with spermicide\]). Exclusion criteria: 1. Participants who reside in countries where the appropriate formulation of perampanel is commercially available. 2. Female participants who are nursing, pregnant, or planning to become pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lennox Gastaut syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy with generalized tonic-clonic seizures focal epilepsy Lennox-Gastaut syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lennox Gastaut syndrome Primary generalized tonic-clonic or partial onset seizures

Contacts and locations

Locations

  • Artroscan

    Ostrava-Trebovice, Czechia

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktató Kórház

    Miskolc, Hungary

  • Centre Neurologique William Lennox

    Ottignies, Belgium

  • Childrens University Hospital

    Riga, Latvia

  • Clinical Centre of Serbia

    Belgrade, Serbia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Dél-Pesti Centrumkórház Országos Hematológiai és Infektológiai Intézet

    Budapest, Hungary

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Hospital Padre Hurtado

    Santiago, Chile

  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Spain

  • Hospital Universitario Virgen del Rocio -

    Seville, Spain

  • Hôpital Universitaire des Enfants Reine Fabiola

    Brussels, Belgium

  • Instytut Psychiatrii Neurologii

    Warsaw, Poland

  • Klaipeda University Hospital

    Klaipėda, Lithuania

  • Magyarorszagi Reformatus Egyhaz (MRE) Bethesda Gyermekkorhaza

    Budapest, Hungary

  • NZOZ Centrum Neurologii Dzieciecej i Leczenia Padaczki

    Kielce, Poland

  • Nzoz Novo-Med

    Katowice, Poland

  • Országos Idegsebészeti Tudományos Intézet

    Budapest, Hungary

  • Oy Neurodiagnostika Ap

    Tallinn, Estonia

  • Pécsi Tudományegyetem

    Pécs, Hungary

  • Rajna és Fiai Kereskedelmi és Szolgáltató Kft.

    Budapest, Hungary

  • Riga 1st Hospital

    Riga, Latvia

  • Servus Salvus Egeszsegugyi Szolgaltato Kft.

    Budapest, Hungary

  • Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu

    Poznan, Poland

  • Tartu University Hospital

    Tartu, Estonia

  • Uniwersyteckie Centrum Kliniczne - PPDS

    Gdansk, Poland

  • Všeobecná fakultní nemocnice, Pragtis s.r.o

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.